Arrowhead Pharma (ARWR)

$17.63 -0.98 (-5.27%)
Market Cap 2.57B
Revenue (ttm) 3.55M
Net Income (ttm) -599.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 186.49
Profit Margin -16,887.04%
Debt to Equity Ratio 0.40
Volume 1,458,700
Avg Vol 1,684,960
Day's Range N/A - N/A
Shares Out 138.10M
Stochastic %K 51%
Beta 0.93
Analysts Strong Sell
Price Target $44.00

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitryp...

Industry: Biotechnology
Sector: Healthcare
Phone: 626 304 3400
Fax: 626 304 3401
Address:
177 East Colorado Boulevard, Suite 700, Pasadena, United States
CDMO
CDMO Jul. 15 at 6:03 PM
$ARWR back in here with 1/3 of inital position. got FOMO
0 · Reply
skeezbag
skeezbag Jul. 15 at 4:59 PM
$ARWR hear that sucking sound? No it aint chris in trumps office. Its the nvidia vacuum and citadel the housekeeper
0 · Reply
JUMBOx_71Torch
JUMBOx_71Torch Jul. 15 at 4:57 PM
$ARWR WKSP ripped: 6,507 shares traded above $4.30 in minutes, no hesitation or pullbacks - float’s evaporating. Feels like true accumulation. I’m long. NFA
0 · Reply
johnnygogogo
johnnygogogo Jul. 15 at 4:30 PM
$ARWR Citadel et al always steals during opex / fed weeks.
0 · Reply
skeezbag
skeezbag Jul. 15 at 3:40 PM
$ARWR cant draw a straighter fucking line to 17
1 · Reply
skeezbag
skeezbag Jul. 15 at 12:08 PM
$ARWR the streak ended at 6 days 70% short volume or greater. On day 7 the short volume was 67% which is still really fucking high and shows you how fake this fucking market is.
1 · Reply
aliliimr
aliliimr Jul. 14 at 10:05 PM
$ARWR accumulate accumulate !!
0 · Reply
skeezbag
skeezbag Jul. 14 at 12:51 PM
$ARWR calling all machines the 9dema crossed the 200dma. Institute keep the chart like shit algo 👾🤖👾🤖👾🤖
0 · Reply
skeezbag
skeezbag Jul. 12 at 11:18 AM
$ARWR 77% short volume. 6 days running over 70% Fuckery is real 17 and lower is the target by Friday
1 · Reply
skeezbag
skeezbag Jul. 11 at 3:40 PM
$ARWR i wish jensen huang would sell his arrowhead shares so the stock price can go up like it does when he sells nvda shares
1 · Reply
Latest News on ARWR
Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Jul 8, 2025, 7:30 AM EDT - 7 days ago

Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jun 23, 2025, 7:30 AM EDT - 22 days ago

Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Jun 4, 2025, 8:02 AM EDT - 5 weeks ago

Jim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Jun 2, 2025, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

May 29, 2025, 7:30 AM EDT - 6 weeks ago

Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

May 12, 2025, 9:56 PM EDT - 2 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

May 12, 2025, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

May 7, 2025, 7:30 AM EDT - 2 months ago

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Apr 30, 2025, 4:01 PM EDT - 2 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Apr 15, 2025, 4:00 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 4, 2025, 4:30 PM EDT - 3 months ago

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Is Finally Arriving

Mar 21, 2025, 5:56 PM EDT - 4 months ago

Arrowhead Pharmaceuticals Is Finally Arriving

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Mar 10, 2025, 7:30 AM EDT - 4 months ago

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Mar 6, 2025, 8:45 AM EST - 4 months ago

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Feb 28, 2025, 9:00 AM EST - 4 months ago

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Feb 25, 2025, 7:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Feb 19, 2025, 11:53 AM EST - 5 months ago

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 5 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

AZN BHVN KROS LLY NVO REGN SRRK

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

Feb 18, 2025, 10:20 AM EST - 5 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

AUB CRK CYTK EXE KRYS MARA MP

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Feb 10, 2025, 9:35 PM EST - 5 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Feb 10, 2025, 4:01 PM EST - 5 months ago

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

Feb 10, 2025, 8:30 AM EST - 5 months ago

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

SRPT

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

Jan 22, 2025, 5:54 PM EST - 6 months ago

Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

B GWRE

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Jan 22, 2025, 4:00 PM EST - 6 months ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Jan 17, 2025, 4:30 PM EST - 6 months ago

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Dec 23, 2024, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Dec 11, 2024, 7:30 AM EST - 7 months ago

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Dec 3, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Dec 2, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Nov 26, 2024, 11:08 PM EST - 8 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Nov 26, 2024, 4:00 PM EST - 8 months ago

Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

Nov 26, 2024, 7:00 AM EST - 8 months ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

SRPT

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Nov 18, 2024, 7:31 AM EST - 8 months ago

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Nov 18, 2024, 7:30 AM EST - 8 months ago

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Nov 5, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Nov 4, 2024, 7:30 AM EST - 9 months ago

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Nov 1, 2024, 7:30 AM EDT - 9 months ago

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Sep 23, 2024, 7:30 AM EDT - 10 months ago

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Sep 10, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Sep 3, 2024, 11:01 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Sep 2, 2024, 6:36 AM EDT - 11 months ago

Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Aug 21, 2024, 7:30 AM EDT - 11 months ago

Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Aug 14, 2024, 6:59 PM EDT - 11 months ago

Arrowhead Pharmaceuticals, Inc. (ARWR) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference (Transcript)

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Aug 14, 2024, 1:30 PM EDT - 11 months ago

Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26, 2024, 12:12 PM EDT - 1 year ago

Arrowhead Pharmaceutical: Driving To Commercialization

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Jul 24, 2024, 7:30 AM EDT - 1 year ago

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

Jun 25, 2024, 2:01 PM EDT - 1 year ago

Canva Upskills 70 Million Educators and Students Globally with New Teacher Certification Course

AGR

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

Jun 25, 2024, 1:55 PM EDT - 1 year ago

Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial

CDMO
CDMO Jul. 15 at 6:03 PM
$ARWR back in here with 1/3 of inital position. got FOMO
0 · Reply
skeezbag
skeezbag Jul. 15 at 4:59 PM
$ARWR hear that sucking sound? No it aint chris in trumps office. Its the nvidia vacuum and citadel the housekeeper
0 · Reply
JUMBOx_71Torch
JUMBOx_71Torch Jul. 15 at 4:57 PM
$ARWR WKSP ripped: 6,507 shares traded above $4.30 in minutes, no hesitation or pullbacks - float’s evaporating. Feels like true accumulation. I’m long. NFA
0 · Reply
johnnygogogo
johnnygogogo Jul. 15 at 4:30 PM
$ARWR Citadel et al always steals during opex / fed weeks.
0 · Reply
skeezbag
skeezbag Jul. 15 at 3:40 PM
$ARWR cant draw a straighter fucking line to 17
1 · Reply
skeezbag
skeezbag Jul. 15 at 12:08 PM
$ARWR the streak ended at 6 days 70% short volume or greater. On day 7 the short volume was 67% which is still really fucking high and shows you how fake this fucking market is.
1 · Reply
aliliimr
aliliimr Jul. 14 at 10:05 PM
$ARWR accumulate accumulate !!
0 · Reply
skeezbag
skeezbag Jul. 14 at 12:51 PM
$ARWR calling all machines the 9dema crossed the 200dma. Institute keep the chart like shit algo 👾🤖👾🤖👾🤖
0 · Reply
skeezbag
skeezbag Jul. 12 at 11:18 AM
$ARWR 77% short volume. 6 days running over 70% Fuckery is real 17 and lower is the target by Friday
1 · Reply
skeezbag
skeezbag Jul. 11 at 3:40 PM
$ARWR i wish jensen huang would sell his arrowhead shares so the stock price can go up like it does when he sells nvda shares
1 · Reply
johnnygogogo
johnnygogogo Jul. 11 at 2:06 PM
$ARWR has a better pipeline and TAM than ALNY. This valuation is so fucking dumb no matter what the price direction is and what the astrological charts say.
1 · Reply
ohkanby
ohkanby Jul. 11 at 12:55 PM
$ARWR $19 previous support gonna be new ceiling? Recent run makes me happy. Stepping back and realizing this dog trading under $20 makes me sad.
0 · Reply
skeezbag
skeezbag Jul. 11 at 12:23 PM
$ARWR 76% short volume. 5 days in a row at or above 70% of volume. Im sure they got wind ahead of time from bofa merrill of kens planned sale
0 · Reply
Mattie2
Mattie2 Jul. 10 at 10:25 PM
$ARWR Tomorrow this turd will probably drop like a lead balloon. Don’t you just have tons of confidence that the SP will EVER go back up for retail shareholders!?!?!🤣
1 · Reply
skeezbag
skeezbag Jul. 10 at 4:14 PM
$ARWR ruler is working again. Turtle head popping through
0 · Reply
CH_Expat
CH_Expat Jul. 10 at 3:54 PM
$ARWR Hey WKSP-Bots, I have a message for you:
0 · Reply
CDMO
CDMO Jul. 10 at 1:46 PM
$ARWR sold. Will be back lower or chasing above 20🤡
1 · Reply
skeezbag
skeezbag Jul. 10 at 12:25 PM
$ARWR 69.2% of volume yesterday was short volume. Im gonna round up and say 4 days straight of about 70% short volume or greater
1 · Reply
RunnerSignals
RunnerSignals Jul. 10 at 3:31 AM
Fresh Breakouts Fuel Trader Buzz $ARWR $MTCH $AMAT $BKNG $AMZN show clean uptrends and momentum. Watching these as potential setups if strength holds https://stocksrunner.com/news/2025-07-09-key-technical-breakouts-and-signals
0 · Reply
simonsp
simonsp Jul. 10 at 1:54 AM
$ARWR Let's grow some legs Anzalone gals
0 · Reply
WARBUD
WARBUD Jul. 10 at 1:31 AM
$ARWR
0 · Reply
Gkal39
Gkal39 Jul. 9 at 11:54 PM
$ARWR 🐻🔨
0 · Reply